Next-Generation MRD Assay May Improve ctDNA Detection in Breast and Colorectal Cancers
A next-generation, whole-genome sequencing (WGS)-based molecular residual disease (MRD) assay detected more circulating tumor DNA (ctDNA)-positive blood samples than an earlier whole-exome sequencing (WES)-based test in patients with triple-negative breast cancer and colorectal cancer. The findings were reviewed during an industry-sponsored Innovation Stage presentation at the 2026 Association for Molecular Pathology (AMP) Annual Meeting & Expo in Seattle.
Abbott commercially launched the next-generation Oncodetect test on October 26, 2026. The tumor-informed assay is performed by Genomic Health, Inc., in a laboratory certified under the Clinical Laboratory Improvement Amendments. The test has not been cleared or approved by the U.S. Food and Drug Administration.
The presentation highlighted findings from two head-to-head comparisons: the PARTNER MRD substudy in triple-negative breast cancer, previously presented at the 2026 ASCO Annual Meeting, and the Beta-CORRECT analysis in colorectal cancer, presented at the 2026 European Society for Medical Oncology (ESMO) Congress.
How the Next-Generation Assay Works
The next-generation Oncodetect assay combines tumor-informed whole-genome sequencing with MAESTRO (Minor Allele Enriched Sequencing Through Recognition Oligonucleotides), a technology originally developed by researchers at the Broad Institute of MIT and Harvard.
The approach preferentially enriches tumor-specific mutations while reducing sequencing of normal DNA, allowing up to 5,000 genetic variants to be monitored more efficiently. The assay has a reported limit of detection below 1 part per million (ppm) under high-input conditions, with analytical specificity exceeding 99%.
Improved Detection in Colorectal Cancer
The Beta-CORRECT analysis compared WGS- and WES-based MRD testing in patients with stage II, III, or resectable stage IV colorectal cancer enrolled in the Japanese GALAXY study. 1
Among 157 paired postsurgical samples, the WGS assay detected all 29 samples identified as ctDNA-positive by the previous-generation WES test, along with 15 additional positive samples. Of these additional detections, 14 (93.3%) occurred at ctDNA concentrations below 10 ppm.
In an analysis of recurrence outcomes, the newer assay also demonstrated greater sensitivity for identifying patients who subsequently experienced recurrence. At 2 years, cumulative sensitivity for recurrence was 72.2% with WGS compared with 42.2% with WES, representing a 30-percentage-point absolute increase.
Postsurgical ctDNA status was prognostic for disease-free survival with both assays. Among patients testing negative with WGS, the 2-year disease-free survival rate was 92.3%. Patients with detectable ctDNA had substantially poorer outcomes, consistent with an increased risk of recurrence.
The investigators also reported associations between postsurgical ctDNA detection and recurrence across evaluated subgroups, including patients with stage II and III disease and those with colon or rectal cancer.
However, the disease-free survival analyses involved nonidentical patient populations.
Greater Sensitivity in Triple-Negative Breast Cancer
The PARTNER MRD substudy evaluated 97 patients with stage II or III triple-negative breast cancer who underwent serial ctDNA testing before, during, and after neoadjuvant chemotherapy and following surgery. 2 The postsurgical analysis included 66 patients, with a median follow-up of 5.0 years.
The WGS assay tracked a median of 3,429 tumor-specific genetic variants per patient, compared with 156 variants using WES. Across the evaluated time points, the newer assay identified ctDNA in more samples, including those with low concentrations of ctDNA. Of the samples testing positive with WGS, 45% had ctDNA concentrations below 10 ppm.
Following surgery, ctDNA was detected in 14 of 66 samples using WGS, compared with 5 of 62 using WES.
Both assays demonstrated significant associations between postsurgical ctDNA status and distant recurrence–free interval. The hazard ratio (HR) for distant recurrence was 52.1 with WGS (95% confidence interval [CI] = 6.5–414.4; P = .0002), compared with an HR of 15.2 with WES (95% CI = 3.5–66.7; P = .0003).
At 3 years, the distant recurrence–free interval rate among patients testing ctDNA-negative was 98.0% with WGS, compared with 90.3% with WES. Among ctDNA-positive patients, the corresponding rates were 39.7% and 30.0%, respectively.
The investigators also examined whether ctDNA status provided prognostic information beyond pathologic complete response. Patients with undetectable postsurgical ctDNA who had not achieved pathologic complete response experienced similarly favorable outcomes vs those who were ctDNA-negative and had achieved pathologic complete response.
In a multivariable analysis, ctDNA positivity remained significantly associated with distant recurrence (HR = 35.4; 95% CI = 3.7–339.4; P = .0020), whereas pathologic complete response status was not independently significant ( P = .4797).
However, the analysis was limited by the small study population and wide confidence intervals.
Summary
The PARTNER and Beta-CORRECT analyses demonstrated that the next-generation assay detected ctDNA at lower concentrations than the earlier assay, potentially improving postoperative risk stratification in patients with triple-negative breast cancer or colorectal cancer. Although the findings support its potential prognostic utility in identifying patients at increased risk of recurrence, its role in guiding surveillance or adjuvant treatment decisions remains to be established. Prospective studies are needed to determine whether assay-guided clinical management improves patient outcomes.
REFERENCES
1. Dooley A, Fontenele RS, Grasse G, et al: Evaluation of whole-exome and whole-genome sequencing tumor-informed circulating tumor DNA MRD assays in patients with early triple-negative breast cancer (TNBC) receiving neoadjuvant chemotherapy (NAC) with or without olaparib: A prospective sub-study of the PARTNER trial. 2026 ASCO Annual Meeting. Abstract 570. Presented June 1, 2026.
2. Hashimoto T, Nakamura Y, Young G, et al: Validation of the ultrasensitive tumor-informed WGS MAESTRO MRD assay in β-CORRECT. ESMO Congress 2026. Abstract 4426P. Presented October 23, 2026.